The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer-Reference-Cited by-同舟云学术

The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer

Published:2024-02-26 Issue:5 Volume:16 Page:939
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Al Saffar Haidar¹,Chen David C.¹²³^ORCID,Delgado Carlos⁴^ORCID,Ingvar Jacob¹,Hofman Michael S.²⁵,Lawrentschuk Nathan¹⁵⁶⁷^ORCID,Perera Marlon¹³,Murphy Declan G.¹²⁵,Eapen Renu¹²³

Affiliation:

1. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia

2. Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia

3. Department of Surgery, Austin Health, Heidelberg, VIC 3084, Australia

4. School of Medicine and Health Sciences, Tecnologico de Monterrey, Monterrey 64849, Mexico

5. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3052, Australia

6. Department of Surgery (Urology), Royal Melbourne Hospital, Melbourne, VIC 3052, Australia

7. EJ Whitten Prostate Cancer Research Centre, Epworth Hospital, Richmond, VIC 3121, Australia

Abstract

The review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abilities of PSMA PET/CT for identifying both nodal and distant PCa, and its potential as a prognostic indicator for biochemical recurrence and overall survival. Additionally, we focused on the variability of PSMA’s expression and its impact on personalised treatment, particularly the use of [177Lu] Lu-PSMA-617 radioligand therapy. This review emphasises the essential role of PSMA PET/CT in enhancing treatment approaches, improving patient outcomes, and reducing unnecessary interventions, positioning it as a key element in personalised PCa management.

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6694/16/5/939/pdf

Reference74 articles.

1. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries from 2000 to 2019;Wang;Front. Public Health,2022

2. Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (ProPSMA): A Prospective, Randomised, Multicentre Study;Hofman;Lancet,2020

3. Prostate-Specific Membrane Antigen Is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase;Carter;Proc. Natl. Acad. Sci. USA,1996

4. Nonprostatic Diseases on PSMA PET Imaging: A Spectrum of Benign and Malignant Findings;Queiroz;Cancer Imaging,2020

5. Lauri, C., Chiurchioni, L., Russo, V.M., Zannini, L., and Signore, A. (2022). PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?. J. Clin. Med., 11.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: PET/CT and MRI in prostate cancer;Frontiers in Oncology;2024-05-24

2. Theranostic digital twins: Concept, framework and roadmap towards personalized radiopharmaceutical therapies;Theranostics;2024